Sell To Pharma Using Patent Timelines
The global pharmaceutical industry is entering a period of wealth transfer that has no historical equivalent. Between 2025 and 2030, […]
Sell To Pharma Using Patent Timelines Read Post »
PTE Denied: The Rules That Kill Patent Term Extensions Before They Start
The $2 Billion Filing Error In March 2000, the USPTO denied a patent term extension application filed by Pfizer for
PTE Denied: The Rules That Kill Patent Term Extensions Before They Start Read Post »
The Drug Name Decoder: A Complete Guide to Generic Pharmaceutical Naming
The Name Behind the Molecule Every drug in clinical use has at least three names. There is the brand name,
The Drug Name Decoder: A Complete Guide to Generic Pharmaceutical Naming Read Post »
The Pre-Filing Due Diligence Playbook: A Comprehensive Guide to Evaluating and Executing Paragraph IV Challenges
Section 1: The Strategic Calculus of a Paragraph IV Challenge The decision to initiate a Paragraph IV (Para IV) challenge
Predicting Generic Entry: How to Leverage Paragraph IV Certifications for Competitive Intelligence
The pharmaceutical industry is entering a historic super-cycle of patent expirations between 2025 and 2030.1 During this window, an estimated
Find the Gaps: How to Identify and Win Low-Competition Generic Drug Launch Opportunities
The Race Nobody Wins Every year, dozens of generic manufacturers file ANDAs for the same thirty drugs. They spend millions
Find the Gaps: How to Identify and Win Low-Competition Generic Drug Launch Opportunities Read Post »
Know Your Cliffs: How to Forecast a Drug’s True Market Longevity Using Patent and Regulatory Exclusivity Data
The Forecast That Keeps Getting Wrong Every year, Wall Street analysts publish revenue forecasts for major pharmaceutical products that prove
Attack First: How to Challenge Drug Patents and Capture Market Exclusivity
The most profitable single legal filing in American commerce is not an M&A deal, a securities offering, or a licensing
Attack First: How to Challenge Drug Patents and Capture Market Exclusivity Read Post »
Predict The Patent Cliff: The Patent Cliff Is Coming. Here’s How to See It First.
A deep-dive guide for investors, analysts, and executives who need to anticipate — not react to — patent expirations that
Predict The Patent Cliff: The Patent Cliff Is Coming. Here’s How to See It First. Read Post »
